CTLA4 and Autoimmunity: As regard to the potential side effect associated with the use of other immune checkpoint targeted drugs such as PD1, PDL1, and CTLA4 toward autoimmunity, it is important to underline that in parallel to the reduction of the Treg/Teff ratio, percentages of activated T effector cells were decreased in vitro.